y-3
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 18, 2025 (NCT07068841)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Disks large homolog 4INHIBITOR
DLG4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07055412 | Phase 1 | Jul 10, 2025 | NeuroDawn Pharmaceutical Co., Ltd. |
| NCT07068841 | Phase 1 | May 18, 2025 | NeuroDawn Pharmaceutical Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeuroDawn Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 1 | 2025 |
1 organizations
Page 1 / 1